Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report
Thymic carcinoma is a rare and aggressive disease with poor outcome. There is no established treatment regimen for advanced thymic carcinoma. While the efficacy of pembrolizumab was proved to be promising, as a single agent, in patients with refractory/recurrent thymic carcinoma that progressed afte...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2022-08-01
|
| Colecção: | Frontiers in Immunology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.941092/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|